Guberina, Nika
Pöttgen, Christoph
Schuler, Martin
Guberina, Maja
Stamatis, Georgios
Plönes, Till
Metzenmacher, Martin
Theegarten, Dirk
Gauler, Thomas
Darwiche, Kaid
Aigner, Clemens
Eberhardt, Wilfried E. E.
Stuschke, Martin
Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Received: 27 February 2022
Accepted: 6 June 2022
First Online: 16 July 2022
Declarations
:
: Approval of the local ethics committee of University of Duisburg-Essen was obtained prior to data collection and analysis [21–10203-BO]. Furthermore, the research was conducted following the statutes of the Declaration of Helsinki 1964.
: Due to the strictly anonymized, retrospective nature of data, informed consent was waived by the local ethics committee of University of Duisburg-Essen [21–10203-BO].
: PD Dr. med. N Guberina, PD Dr. med. M Guberina, Dr. med. M Metzenmacher, Prof. Dr. med. K Darwiche, PD Dr. med. T Ploenes, Prof. Dr. med. M Schuler, Prof. Dr. med. D Theegarten, Prof.. Dr. med. G. Stamatis, Prof. Dr. med. C Aigner: There are no relationships/conditions/circumstances that present a potential conflict of interest. All authors declare that they have no conflict of interest. Prof. Dr. med. C Pöttgen reports personal fees from Roche Pharma, personal fees from Boehringer Ingelheim, personal fees from Astra Zeneca, all outside the submitted work; .There are no relationships/conditions/circumstances that present a potential conflict of interest. PD Dr. med. W:E:E. Eberhardt reports honoraria (Advisory board function) from Astra Zeneca, BMS, Roche, MSD, Pfizer, Boehringer, Takeda, Eli Lilly, Bayer, Celgene Honoraria, and (educational lectures) from BMS, MSD Astra Zeneca, Roche, Novartis, Pfizer, Boehringer, Takeda, Abbvie, Celgene, Eli Lilly as well as (research grants) from Eli Lilly, BMS, and Astra Zeneca. The author declares that no competing interests exist. Dr med. T. Gauler reports advisory board/consultant function for Ipsen, No-vartis, BMS, Eisai and honoraria from BMS, Ipsen, Novartis, MSD, Eisai, Pfizer as well as traveling expenses from BMS, Ipsen, Novartis, MSD, Eisai, Pfizer and stocks from Bayer. Prof. Dr. med. M. Stuschke reports research grants contributed by AstraZeneca in 2019 and 2020. Professor Dr.med. M. Stuschke confirms that the above mentioned funding source was not involved in the study design or materials used, nor in the collection, analysis, and interpretation of data nor in the writing of the paper.